Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Mar;1(2):281-8.
doi: 10.2217/1750743X.1.2.281.

Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder

Timothy P Kresowik  1 , Thomas S Griffith
Affiliations
Review

Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder

Timothy P Kresowik et al. Immunotherapy. 2009 Mar.

Abstract

Mycobacterium bovis bacille Calmette-Guerin (BCG) is one of the great success stories of immunotherapy as a treatment for superficial urothelial carcinoma of the bladder. Despite clinical effectiveness in over 50% of patients, the high incidence of local side effects and presence of nonresponders has led to efforts to improve the therapy. Recent advances have suggested a role for neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in the antitumor inflammatory response. Cell wall components of mycobacteria alone, lowered doses of BCG, and combination with cytokines have been studied as ways to improve the immune response associated with BCG and/or reduce toxicity. This review will discuss the clinical use of BCG, its proposed mechanism of action, and directions of future research to improve efficacy and decrease side effects.

Keywords: BCG; Guerin; TRAIL; bacillus Calmette; bladder cancer; neutrophil; urothelial carcinoma.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Postulated mechanism of action of bacillus Calmette–Guerin
(A) BCG infection of urothelial cells leads to the release of cytokines, such as IL-8. (B) Neutrophils compose the early responding cells to BCG; BCG stimulates release of TRAIL in addition to chemotactic factors. (C) Inflammatory effector cells, such as T cells and macrophages, respond to the neutrophil-secreted chemotactic signals. (D) Cytotoxic cells and TRAIL lead to tumor apoptosis. BCG: Bacille Calmette–Guerin; TRAIL: TNF-related apoptosis-inducing ligand.
See this image and copyright information in PMC

References

Bibliography

    1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2008;58:71–96. - PubMed
    1. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics. 2003;21:1315–1330. - PubMed
    1. Konety BR, Joyce GF, Wise M. Bladder and upper tract urothelial cancer. J Urol. 2007;177:1636–1645. - PubMed
    1. Morales A, Eidinger D, Bruce AW. Intracavitary bacillus Calmette–Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116:180–183. - PubMed
    1. Herr HW, Laudone VP, Badalament RA, et al. Bacillus Calmette–Guerin therapy alters the progression of superficial bladder cancer. J Clin Oncol. 1988;6:1450–1455. - PubMed
Website
    1. Clinical.Trials.gov . www.clinicaltrials.gov.

Publication types

MeSH terms

Substances